Chapter 14 Apheresis
The replacement fluid indicated during plasma exchange for TTP is: a. Normal (0.9%) saline. b. Hydroxyethyl starch (HES). c. FFP. d. Albumin (human) 5%.
c. FFP
Peripheral blood stem cells are: a. Responsible for phagocytosis of bacteria. b. Removed during erythrocytapheresis. c. Pluripotential hematopoietic precursors that circulate in the peripheral blood. d. Lymphocytes involved with the immune response.
c. Pluripotential hematopoietic precursors that circulate in the peripheral blood.
The anticoagulant added to blood as it is removed from a donor or patient during an apheresis procedure acts by: a. Binding calcium ions. b. Increasing intracellular potassium. c. Binding to antithrombin d. Inactivating factor V
a. Binding calcium ions.
In plasma exchange, the therapeutic effectiveness is: a. Greatest with the first plasma volume removed b. Affected by the type of replacement fluid used c. Enhanced if the unwanted antibody is IgG rather than IgM d. Independent of the use of concomitant immunosuppressive therapy
a. Greatest with the first plasma volume removed
Therapeutic cytapheresis has a primary role in treatment of patients with: a. Sickle cell disease and acute chest syndrome. b. Systemic lupus erythematosus to remove immune complexes. c. Leukemia to help increase granulocyte production. d. Myasthenia gravis to increase antibody production.
a. Sickle cell disease and acute chest syndrome.
The minimum interval allowed between plateletpheresis component collection procedures is: a. 1 day. b. 2 days. c. 7 days. d. 8 weeks
b. 2 days.
Apheresis technology can be used to collect each of the following components except: a. Leukocytes. b. Macrophages. c. Hematopoietic progenitor cells. d. Platelets.
b. Macrophages
The most common adverse effect of plateletpheresis collection is: a. Allergic reaction. b. Hepatitis. c. Hemolysis. d. Citrate effect.
d. Citrate effect.
The most common anticoagulant used for apheresis procedures is: a. Heparin. b. Sodium fluoride. c. Warfarin d. Citrate.
d. Citrate.
Which of the following can be given to an apheresis donor to increase the number of circulating granulocytes? a. DDAVP b. Hydroxyethyl starch (HES) c. Immune globulin d. G-CSF
d. G-CSF
